Antibody-Drug Conjugate– tag –
-
Lonza Offers Integrated ADC Clinical and Commercial Manufacturing Services, Covering Antibody to Sterile Fill-Finish
Lonza Switzerland Overview Lonza offers integrated development and manufacturing services for Antibody-Drug Conjugates (ADCs), encompassing antibodies, payloads, bioconjugation, and sterile fill and finish. The company operates GMP produ... -
Pfizer Discontinues Seagen-Developed Solid Tumor ADC Program SGN-MesoC2, Highlighting Persistent ADC Development Challenges
BioSpace USA Overview Pfizer has discontinued another Seagen-developed antibody-drug conjugate (ADC) program for solid tumors, SGN-MesoC2, just weeks after another Seagen-acquired ADC failed a Phase 3 lung cancer study. This cessation un... -
Antibody-Drug Conjugates Show Significant Clinical Activity and Promise in Biliary Tract Cancers
CCA News Online USA Overview Antibody-drug conjugates (ADCs) are emerging as a significant class of cancer therapeutics for biliary tract cancers (BTCs), offering improved outcomes in difficult-to-treat tumors. Advances in ADC technology... -
ASCO Podcast: Optimizing Frontline ADCs as They Shift to Earlier Cancer Treatment Stages
ASCO Publications USA Overview An ASCO Publications podcast discusses the rapid integration of antibody-drug conjugates (ADCs) into frontline advanced and curative-intent perioperative settings for cancer treatment. Experts emphasize tha... -
Optimized NAMPT Inhibitors Enable Highly Effective ADCs for Liquid and Solid Tumors, Achieving Complete Regressions in Preclinical Models
ACS Bio & Med Chem Au USA Overview This publication details the development of next-generation NAMPT inhibitors as ADC payloads through physicochemical and metabolic optimization. When conjugated to anti-CD30, anti-HER2, or anti-TROP2 an... -
Modular In Vivo Antibody-ADC Click Strategy Reverses Drug Resistance in Tumors
PubMed (Nature Chemical Biology) USA Overview Researchers have introduced an in vivo bioorthogonal ligation strategy to generate functional antibody-drug conjugate (ADC) click constructs following systemic administration. This modular pl... -
Optimal Payload Linker Selection is Critical for ADC Development, Balancing Efficacy, Safety, and Stability
Chemexpress China Overview This guide highlights the critical role of selecting the right payload linker for successful antibody-drug conjugate (ADC) programs. Linker design dictates the balance between efficacy, safety, stability, and m... -
Merck/Kelun-Biotech ADC Candidate Sac-TMT Demonstrates Superior Progression-Free Survival Over Chemotherapy in China Phase 3 Lung Cancer Study
Endpoints News USA Overview Merck's partner Kelun-Biotech announced positive Phase 3 study results in China for sac-TMT, an experimental antibody-drug conjugate (ADC). In non-squamous non-small cell lung cancer, sac-TMT combined with imm... -
Lonza Boosts Biologics Manufacturing with Dual Expansion: Swiss ADC Capacity and Enhanced US Biopharma Partnership with N-1 Perfusion Technology
Industry Week USA Overview Lonza has significantly strengthened its biopharmaceutical manufacturing capabilities through a massive expansion of its Antibody-Drug Conjugate (ADC) production capacity in Switzerland and an extended long-ter... -
Gyros Protein Technologies Streamlines Biotherapeutic Impurity Testing with Automated Immunoassay Platform: Enhancing Reproducibility and Throughput
Bioprocess International (via Gyros Protein Technologies webcast summary) USA Overview Gyros Protein Technologies is addressing impurity testing challenges in biotherapeutic development with its Gyrolab automated immunoassay platform. Th...
